Pharmacists play a significant role in oncology with respect to the safe handling and administration of anti-cancer drugs. This comprehensive review analyses pharmacists' roles, emphasising adherence to national and international safety standards and the implementation of institutional programs for protocols, training, and certification. Pharmacists will aid in the formulation and adjustment of chemotherapy medications through Personal Protective Equipment kits and working practices. Among administration methods, intravenous chemotherapy, oral anticancer agents, and special routes, such as intrathecal, can be used. Other notable responsibilities of pharmacists' work are medication safety, occupational exposure risk, and pharmacovigilance. Pharmacists can gain practical insights through case studies and possibly help prevent and control errors by implementing systemic strategies. Pharmacists are also involved in counselling and teaching patients for treatment, managing side effects, and other policies that enhance compliance. This review provides valuable insights into interprofessional collaboration to improve patient safety and achieve optimal outcomes. Emerging technologies and innovations are having a growing impact on medication management, and pharmacists have been recognised as playing a vital role in ensuring safe adoption in oncology practice. Continuous education and professional development enable pharmacists to stay up to date on the latest advancements, providing the best possible care. This review discusses the essential contributions pharmacists make to the oncology department by improving the care, safety, and efficacy of anticancer treatment, demonstrating their commitment to excellence and adaptability in healthcare settings.

Background The diagnosis of drug-induced liver injury (DILI) is difficult due to insufficient awareness of DILI and the lack of specific objective diagnostic tests. The importance of pharmacists' care during hospitalization is underestimated. Our aim is to review the clinical features of fluoroquinolone-induced liver injury and to highlight the importance of pharmacists' intervention in fluoroquinolone-induced liver injury. . Case presentation: An 81-year-old Chinese man was admitted to hospital for the treatment of community-acquired pneumonia. After admission, he developed chronic subdural hematoma as his condition deteriorated, followed by intracranial infection after the cranial trepanation. On day 15, the patient still presented with fever and altered consciousness. Moxifloxacin (IV, 400 mg QD) was administered as the pulmonary infection became worse. Elevated liver enzymes were then observed with alanine aminotransferase (ALT) rising from 27 U/L to 387 U/L after the three-day use of moxifloxacin. With the help of pharmacists' interventions, drug-induced liver injury was identified. Moxifloxacin was discontinued immediately and replaced with meropenem (IV, 1g, Q8h). Within another 7 days, the patient's fever subsided, liver function normalized, and consciousness improved. He was successfully discharged from the hospital 30 days after admission. Written informed consent was obtained from the patient. Ethics approval was waived by the Institutional Review Board of Taikang Tongji (Wuhan) Hospital. Conclusions: Fluoroquinolone-induced liver injury are rare but can be lethal. Pharmacists' interventions enable collaborative decision-making and can help improve the management in fluoroquinolone-induced liver injury.